hu.MAP 2.0: Complex View
Human Protein Complex Map
Search for a protein
Complex: HuMAP2_05332
Confidence: High
Proteins| Genename | Protein Name | Links |
|---|---|---|
| ADI1 | 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase (EC 1.13.11.54) (Acireductone dioxygenase (Fe(2+)-requiring)) (ARD) (Fe-ARD) (Membrane-type 1 matrix metalloproteinase cytoplasmic tail-binding protein 1) (MTCBP-1) (Submergence-induced protein-like factor) (Sip-L) | UniProt NCBI |
| EIF2B1 | Translation initiation factor eIF-2B subunit alpha (eIF-2B GDP-GTP exchange factor subunit alpha) | UniProt NCBI |
| EIF2B5 | Translation initiation factor eIF-2B subunit epsilon (eIF-2B GDP-GTP exchange factor subunit epsilon) | UniProt NCBI |
| EIF2B2 | Translation initiation factor eIF-2B subunit beta (S20I15) (S20III15) (eIF-2B GDP-GTP exchange factor subunit beta) | UniProt NCBI |
| EIF2B4 | Translation initiation factor eIF-2B subunit delta (eIF-2B GDP-GTP exchange factor subunit delta) | UniProt NCBI |
| EIF2B3 | Translation initiation factor eIF-2B subunit gamma (eIF-2B GDP-GTP exchange factor subunit gamma) | UniProt NCBI |
Enrichments
| Term ID | Corrected Pval | Fraction Complex Coverage | Proteins | Term Name |
|---|---|---|---|---|
| CORUM:7292 | 6.09820937128e-17 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | EIF2B1-EIF2B2-EIF2B3-EIF2B4-EIF2B5 complex |
| HP:0031212 | 5.46128528139e-16 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormal circulating progesterone level |
| HP:0008233 | 5.46128528139e-16 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Decreased circulating progesterone |
| HP:0004485 | 3.27658776883e-15 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Cessation of head growth |
| REAC:R-HSA-72731 | 9.0230347994e-15 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Recycling of eIF2:GDP |
| GO:0005851 | 2.94892899195e-13 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | eukaryotic translation initiation factor 2B complex |
| CORUM:7291 | 4.54011687692e-13 | 0.666666666667 | EIF2B2 EIF2B4 EIF2B5 EIF2B3 | EIF2B2-EIF2B3-EIF2B4-EIF2B5 complex |
| HP:0008193 | 2.38402074369e-12 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Primary gonadal insufficiency |
| HP:0006808 | 3.37717357369e-12 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Cerebral hypomyelination |
| WP:WP107 | 8.58496556423e-11 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Translation Factors |
| HP:0000751 | 9.26582104073e-11 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Personality changes |
| HP:0007305 | 1.09810982867e-10 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | CNS demyelination |
| GO:0014003 | 2.14561866932e-10 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | oligodendrocyte development |
| HP:0000746 | 2.37629421638e-10 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Delusions |
| HP:0000869 | 3.13838957909e-10 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Secondary amenorrhea |
| HP:0003429 | 5.91805320432e-10 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | CNS hypomyelination |
| HP:0008209 | 1.03883912036e-09 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Premature ovarian insufficiency |
| HP:0031066 | 4.49581184122e-09 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormal ovarian physiology |
| GO:0048709 | 4.82439758657e-09 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | oligodendrocyte differentiation |
| HP:0002171 | 1.3073826817e-08 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Gliosis |
| HP:0003621 | 1.57872881449e-08 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Juvenile onset |
| HP:0000786 | 1.89334106094e-08 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Primary amenorrhea |
| REAC:R-HSA-72613 | 2.80175002575e-08 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Eukaryotic Translation Initiation |
| REAC:R-HSA-72737 | 2.80175002575e-08 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Cap-dependent Translation Initiation |
| KEGG:03013 | 2.95195270384e-08 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | RNA transport |
| GO:0003743 | 3.67598690243e-08 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | translation initiation factor activity |
| HP:0000712 | 4.7546538562e-08 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Emotional lability |
| HP:0002354 | 4.7546538562e-08 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Memory impairment |
| HP:0002317 | 4.99450679057e-08 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Unsteady gait |
| HP:0000141 | 8.70490895085e-08 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Amenorrhea |
| GO:0021782 | 9.34955208324e-08 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | glial cell development |
| HP:0100705 | 1.07861441229e-07 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of the glial cells |
| HP:0005484 | 1.22141883003e-07 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Postnatal microcephaly |
| HP:0001254 | 1.74269349063e-07 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Lethargy |
| HP:0002352 | 2.25996161815e-07 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Leukoencephalopathy |
| GO:0008135 | 6.37584963648e-07 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | translation factor activity, RNA binding |
| HP:0000140 | 6.59047852865e-07 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of the menstrual cycle |
| GO:0009749 | 6.85127440347e-07 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | response to glucose |
| HP:0000858 | 7.60993923196e-07 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Menstrual irregularities |
| GO:0034284 | 8.45002432374e-07 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | response to monosaccharide |
| GO:0009746 | 8.45002432374e-07 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | response to hexose |
| HP:0011400 | 8.51305159345e-07 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormal CNS myelination |
| HP:0000137 | 9.24499563139e-07 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of the ovary |
| GO:0010001 | 1.03340357333e-06 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | glial cell differentiation |
| GO:0009743 | 1.3353372641e-06 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | response to carbohydrate |
| GO:0090079 | 1.80780816889e-06 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | translation regulator activity, nucleic acid binding |
| HP:0000618 | 2.31672863855e-06 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Blindness |
| HP:0001945 | 2.31672863855e-06 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Fever |
| REAC:R-HSA-72766 | 2.61823790042e-06 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Translation |
| KEGG:05168 | 2.82771996883e-06 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Herpes simplex virus 1 infection |
| GO:0042063 | 3.49697918628e-06 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | gliogenesis |
| HP:0002376 | 5.0295367295e-06 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Developmental regression |
| GO:0045182 | 5.98038175538e-06 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | translation regulator activity |
| HP:0004372 | 6.19822959836e-06 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Reduced consciousness/confusion |
| HP:0004370 | 7.98907677784e-06 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of temperature regulation |
| GO:0009408 | 8.18370793251e-06 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | response to heat |
| HP:0003117 | 1.06952275458e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormal circulating hormone level |
| HP:0040194 | 1.40880749661e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Increased head circumference |
| HP:0000256 | 1.40880749661e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Macrocephaly |
| GO:0009266 | 2.03396545633e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | response to temperature stimulus |
| HP:0007663 | 2.73427738257e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Reduced visual acuity |
| GO:0050852 | 3.08409640217e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | T cell receptor signaling pathway |
| HP:0012447 | 3.13277266266e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormal myelination |
| GO:0005085 | 3.29490647507e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | guanyl-nucleotide exchange factor activity |
| GO:0006413 | 5.11490390245e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | translational initiation |
| HP:0001260 | 5.152434407e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Dysarthria |
| HP:0000008 | 6.16120223464e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of female internal genitalia |
| HP:0031466 | 7.57342021469e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Impairment in personality functioning |
| GO:0050851 | 8.54986059513e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | antigen receptor-mediated signaling pathway |
| HP:0000812 | 8.84109497817e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormal internal genitalia |
| HP:0000648 | 9.84601326275e-05 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Optic atrophy |
| HP:0010460 | 0.000112864715349 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of the female genitalia |
| HP:0410280 | 0.000125049791476 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Pediatric onset |
| HP:0100543 | 0.000146708649501 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Cognitive impairment |
| HP:0008373 | 0.000168023490221 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Puberty and gonadal disorders |
| HP:0012795 | 0.00016963556064 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of the optic disc |
| GO:0043434 | 0.000199221003427 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | response to peptide hormone |
| HP:0000587 | 0.000380472875791 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of the optic nerve |
| HP:0001257 | 0.00045680210851 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Spasticity |
| GO:1901652 | 0.000537394564545 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | response to peptide |
| GO:0002429 | 0.000693957239919 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | immune response-activating cell surface receptor signaling pathway |
| GO:0001541 | 0.000824951429902 | 0.5 | EIF2B2 EIF2B5 EIF2B4 | ovarian follicle development |
| GO:0002768 | 0.000995084496271 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | immune response-regulating cell surface receptor signaling pathway |
| HP:0001288 | 0.00109069867567 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Gait disturbance |
| HP:0000505 | 0.00114894594913 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Visual impairment |
| HP:0001276 | 0.00115639761438 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Hypertonia |
| HP:0001290 | 0.00159074418617 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Generalized hypotonia |
| HP:0002167 | 0.00213381855934 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Neurological speech impairment |
| HP:0003674 | 0.0023356695228 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Onset |
| HP:0000252 | 0.0025384284618 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Microcephaly |
| HP:0040195 | 0.00259479391269 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Decreased head circumference |
| HP:0000504 | 0.00287628702715 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of vision |
| HP:0001098 | 0.00305002869114 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormal fundus morphology |
| HP:0004329 | 0.00309883200414 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormal posterior eye segment morphology |
| GO:0008585 | 0.0032070828615 | 0.5 | EIF2B2 EIF2B5 EIF2B4 | female gonad development |
| GO:0046545 | 0.0032070828615 | 0.5 | EIF2B2 EIF2B5 EIF2B4 | development of primary female sexual characteristics |
| HP:0002493 | 0.00353015858565 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Upper motor neuron dysfunction |
| GO:0051020 | 0.00361538513796 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | GTPase binding |
| HP:0000818 | 0.00392821369626 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of the endocrine system |
| GO:0002757 | 0.00458117674614 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | immune response-activating signal transduction |
| HP:0012243 | 0.00460260679195 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormal reproductive system morphology |
| GO:0007417 | 0.0051052681599 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | central nervous system development |
| GO:0046660 | 0.00529364410104 | 0.5 | EIF2B2 EIF2B5 EIF2B4 | female sex differentiation |
| HP:0012337 | 0.00589194192936 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormal homeostasis |
| GO:0002764 | 0.00594566736806 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | immune response-regulating signaling pathway |
| HP:0007364 | 0.00616985985338 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Aplasia/Hypoplasia of the cerebrum |
| HP:0000240 | 0.00761896072068 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of skull size |
| HP:0000078 | 0.00813428041016 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of the genital system |
| GO:0009725 | 0.00924535078845 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | response to hormone |
| GO:0002253 | 0.00944223313621 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | activation of immune response |
| HP:0000708 | 0.0116486917565 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Behavioral abnormality |
| HP:0031797 | 0.0125172292132 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Clinical course |
| GO:0006412 | 0.0137308239878 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | translation |
| HP:0002977 | 0.0138079720554 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Aplasia/Hypoplasia involving the central nervous system |
| HP:0001252 | 0.0138617140676 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Muscular hypotonia |
| GO:0010243 | 0.0170964795605 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | response to organonitrogen compound |
| GO:0043043 | 0.0170964795605 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | peptide biosynthetic process |
| HP:0001250 | 0.0190757028291 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Seizures |
| HP:0011442 | 0.0217047722773 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of central motor function |
| HP:0002060 | 0.0221695518784 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of the cerebrum |
| GO:0050778 | 0.0222446676534 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | positive regulation of immune response |
| REAC:R-HSA-392499 | 0.0232605972232 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Metabolism of proteins |
| HP:0100547 | 0.0235294088503 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of forebrain morphology |
| GO:1901566 | 0.0302488967756 | 1.0 | EIF2B2 EIF2B3 EIF2B1 EIF2B4 ADI1 EIF2B5 | organonitrogen compound biosynthetic process |
| GO:1901698 | 0.0305316212101 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | response to nitrogen compound |
| HP:0003808 | 0.0330338259598 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormal muscle tone |
| HP:0100022 | 0.0360288496277 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormality of movement |
| GO:0043604 | 0.0420836853755 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | amide biosynthetic process |
| GO:0006518 | 0.0430733890744 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | peptide metabolic process |
| GO:0008406 | 0.0447070305646 | 0.5 | EIF2B2 EIF2B5 EIF2B4 | gonad development |
| HP:0000929 | 0.0467452239687 | 0.833333333333 | EIF2B1 EIF2B3 EIF2B4 EIF2B5 EIF2B2 | Abnormal skull morphology |
| GO:0045137 | 0.0472791215337 | 0.5 | EIF2B2 EIF2B5 EIF2B4 | development of primary sexual characteristics |
| GO:0042552 | 0.0472791215337 | 0.5 | EIF2B2 EIF2B5 EIF2B4 | myelination |
Edges
| Protein 1 | Protein 2 | Score | Precision | Evidence |
|---|---|---|---|---|
| EIF2B3 | EIF2B4 | 1.0 | 0.949 | bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B2 | EIF2B5 | 1.0 | 0.949 | bioplex (EIF2B2) bioplex_WMM boldt Malo fraction boldt_WMM |
| EIF2B2 | EIF2B4 | 1.0 | 0.949 | bioplex (EIF2B2) bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B2 | EIF2B3 | 1.0 | 0.949 | bioplex (EIF2B2) bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B2 | EIF2B1 | 1.0 | 0.949 | hein_WMM bioplex (EIF2B1,EIF2B2) bioplex_WMM boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B1 | EIF2B5 | 1.0 | 0.949 | bioplex (EIF2B1) bioplex_WMM boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B5 | EIF2B4 | 1.0 | 0.949 | bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B1 | EIF2B3 | 1.0 | 0.949 | bioplex (EIF2B1) bioplex_WMM boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B5 | EIF2B3 | 1.0 | 0.949 | bioplex_WMM Guru boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B1 | EIF2B4 | 1.0 | 0.949 | bioplex (EIF2B1) bioplex_WMM boldt youn_WMM Malo fraction boldt_WMM |
| EIF2B1 | ADI1 | 0.612 | 0.674 | bioplex_WMM fraction |
Images
Click to enlarge
Complex HuMAP2_05332 has an average edge precision of 0.924 which is ranked 459 out of all 6965 complexes.
Related Complexes
| Genename | Complexes |
|---|---|
| ADI1 | HuMAP2_03847 HuMAP2_05332 HuMAP2_05641 |
| EIF2B1 | HuMAP2_02528 HuMAP2_03847 HuMAP2_05332 |
| EIF2B5 | HuMAP2_02528 HuMAP2_03804 HuMAP2_05332 |
| EIF2B2 | HuMAP2_00931 HuMAP2_02528 HuMAP2_03804 HuMAP2_05332 |
| EIF2B4 | HuMAP2_02528 HuMAP2_03804 HuMAP2_05332 |
| EIF2B3 | HuMAP2_02528 HuMAP2_03804 HuMAP2_05332 |